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been shown to be unhelpful in the diagnosis of fungal
disease. We therefore initiated the practice of nasal
endoscopy as part of our evaluation of HSCT patients who
had prolonged fever.
Methods: We performed a retrospective review of all
children who underwent HSCT at our institution from
January 2011 until June 2014. Children were identiﬁed who
underwent nasal endoscopy after a minimum of three days
of fever despite the initiation of broad-spectrum antibiotics
and who had negative bacterial blood cultures. The results of
the endoscopy and any cultures obtained were reviewed.
Demographic, clinical, microbiologic, management and
outcome data were collected.
Results: A total of 44 nasal endoscopieswereperformed in 42
children. Threeof the childrenhadpositivenasal endoscopies.
Two were asymptomatic and were found to have suspicious
lesions which were subsequently biopsied. Thesewere found
to be positive for Fusarium spp andRhizopus spp. The thirdhad
rapid development of eye swelling and sinus pain and was
found to have Rhizopus spp. The three children were then
treated with aggressive serial debridement and initiation of
multiagent antifungal therapy. All three of the children sur-
vived their fungal infection although one remains on anti-
fungal therapy.Mild discomfort during the procedurewas the
onlyadverse event related to the use of endoscopy reported in
this patient group. In those with a negative endoscopy, there
were no children who subsequently developed fungal sinus
disease. Three of these patients were later identiﬁed with a
fungal infection at other sites: one had bipolaris spp of the
skin, one had Aspergillus ﬂavus isolated from an endotracheal
tube aspirate and one had disseminated Histoplasmosis
capsulatum isolated on post-mortem examination.
Conclusions: We conclude that nasal endoscopy is safe and
effective in the evaluation of pediatric HSCT patients as part
of the evaluation of prolonged fever to rule out fungal
sinusitis. Early detection of fungal sinusitis by nasal
endoscopy and aggressive surgical and antifungal therapy
may improve the survival of HSCT patients.332
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Introduction: Letermovir (MK-8228) is a potent, once-daily
inhibitor of the cytomegalovirus (CMV) terminase complex
that is being developed for the prophylaxis of CMV
infection in transplant patients. This study evaluated the
pharmacokinetic interactions, safety and tolerability of
letermovir when coadministered in healthy subjects with
mycophenolate mofetil (MMF), which is the morpholi-
noethyl ester prodrug of mycophenolic acid (MPA).
Materials & Methods: This was an open label trial in 14
healthy female subjects that explored the pharmacokidsnetic
parameters of a single 1 mg oral dose of MMF administered
alone on day 1 and administered on day 12 with letermovir
given orally as 480 mg once daily from day 8 and continued
through day 16. Letermovir pharmacokinetics were assessedat single dose (day 5) and at steady state on day 12 (with
MMF) and on day 16 (alone following MMF washout).
Results: Coadministration of a single dose of 1 mg of MMF
with 480 mg daily letermovir at steady state had no effect on
the pharmacokinetics of MPA. The MPA AUC0-inf and Cmax
geometric mean ratios (GMRs) [90% conﬁdence interval] for
the comparison (MMF with letermovir/MMF alone) were
1.08 [0.96, 1.21] and 0.96 [0.81, 1.13], respectively. Coadmin-
istration of 480 mg daily letermovir at steady state with a
single dose of 1 mg MMF has no clinically meaningful effect
on the pharmacokinetics of letermovir with AUC0-24 and
Cmax GMR of 1.18 [1.04, 1.33] and 1.11 [0.92, 1.35], respec-
tively. The letermovir geometric mean accumulation ratio
(Day 16/Day 5) and 95% CI were 1.13 [0.90, 1.42] for AUC0-24
and 1.01 [0.79, 1.28] for Cmax, indicating that accumulation of
letermovir when administered as daily doses is minimal. All
related AEs were reported as mild in severity and resolved.
Following coadministration of letermovir and MMF, no
clinically meaningful changes were observed in clinical
laboratory values, vital signs, ECG or physical exam results.
Conclusions: Multiple dose administration of 480 mg leter-
movirdailywith a single doseof 1mgMMFwasgenerallywell
tolerated by the healthy subjects in this study. Co-adminis-
tration of letermovir with MMF had no clinically meaningful
effect on the PK of letermovir or MMF. Letermovir and MMF
may be coadministered without dose adjustment.333
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Introduction: While AH & ITP are recognized after CBT, the
incidence, severity, treatment response, & prognosis of these
complications is not established.
Methods: We evaluated AH/ITP in a day 100 landmark
analysis of 152 double-unit CBT recipients (median age 38
years, range 0.9-70) who were transplanted for hematologic
malignancies, engrafted & disease-free.
Results: Nine patients [median age 42 years (range 2-54),
median follow-up 50.6 months (range 7.6-105.4) have
developed autoimmune cytopenias (7 AH, 1 ITP, 1 both) for a
6% (95%CI: 3-11) 3-year cumulative incidence [median onset
8.6 months (range 5.8-24.5), Figure]. Six patients had severe
disease (Hb < 6 gm/dl &/or platelets < 20). Their lowest
counts (Hb 2.6-6.8 & platelets 0-4) were a median of 1 day
(range 0-94) after diagnosis. Six had grade II-IV acute
GVHD prior to AH/ITP, and all 9 patients developed AH/ITP
in the context of immunosuppression taper. There was no
association between AH/ITP and age, diagnosis, regimen
intensity, or recipient CMV serostatus. Treatment in the
ﬁrst week was IVIg/corticosteroids/rituximab in 3 patients,
whereas CSA dose was increased in 1, 2 had IVIg only, 2
Figure.
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all 9 patients received rituximab at 2-18 days (4-6 doses)
after diagnosis. Early rituximab ( 7 days) reduced time to
CR (Hb  8 &/or platelets  100): median 13 days (7-49
days) if early rituximab in 4 patients versus 58 days (19-98
days) in 5 without early rituximab. Moreover, an initial
IVIg/corticosteroids/rituximab combination was best (CR 7-
13 days). Four patients ﬂared at 28-393 days but all
achieved CR with further treatment. Drug therapy was well
tolerated whereas 2 of 3 patients who underwent
splenectomy with initial therapy or with relapse had
complications. Eight of 9 AH/ITP patients are alive &
disease free. Seven of them are in CR from AH/ITP at a
median of 30 months (range 9-102) follow-up after AH/ITP
diagnosis whereas one has recurrent AH requiring therapy.
Conclusions: While AH/ITP is infrequent it can have sudden
onset and be life-threatening. The mechanism is likely
transient B-cell immune dysregulation during immunosup-
pression taper, and thus patient monitoring and prompt
recognition during this period are warranted. Early
rituximab treatment is both mandated at presentation in
severe disease and will likely reduce corticosteroid exposure
& could avoid splenectomy.334
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Background: Reactivation of cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) following allogeneic stem cell
transplant occurs in 60-70% and 5-15% of patients
respectively. CMV disease can present as pancytopenia,
disordered liver function, pneumonitis, retinitis or
neurological disorders. EBV reactivation can result in post
transplant lymphoproliferative disorder (PTLD). At risk
patients are monitored using DNA PCR assays and
pre-emptive therapy commenced. The optimum timing for
intervention has not been established.
Methods: We identiﬁed at-risk patients receiving an
allogeneic transplant during the period 2012-2013 from ourinstitutional database and retrospectively collected data
from the electronic and paper records.
Results: Complete data was available for 27 patients. The
diagnoses were AML/MDS (14), ALL (6), CLL (3), CML (1),
aplastic anaemia (1) andmyeloﬁbrosis (1). 26 were at risk for
EBV reactivation and 13 were at risk for CMV reactivation.
5/13 (38%) patients developed CMV reactivation at a median
of 26 days post transplant (range 22-49). The median CMV
DNA peak titre was 3647 IU/ml (range 603-62616). 4/5
patients were treated with valganciclovir and none
developed CMV disease. Valganciclovir was well tolerated
and effective in all cases. 7/26 patients (27%) developed EBV
reactivation after amedian 60 days (range 10-221). 2 patients
(12.5%) developed lymphadenopathy and received rituximab
with a complete response. Two patients developed late onset
recurrent EBV reactivation following treatment with
rituximab. One patient had a rising titre from day +165,
continuing to rise from <137 to 37944 IU/ml on day +494.
The second patient reactivated on day +225 with a titre
continuing to rise to 23693 IU/ml on day +264. Neither
patient was on immunosuppression or has developed clinical
or radiological evidence of PTLD.
Conclusion: CMV reactivation was less frequent than
previously reported and pre-emptive therapy was effective.
It is possible that some patients were treated unnecessarily
although treatment was well tolerated. EBV reactivation
rates were consistent with those previously reported. Two
cases of PTLD highlight the importance of regular EBV titre
monitoring and early treatment. The late re-emergence
of EBV reactivation in patients who are not on immuno-
suppression is not well described in the literature and its
pathogenesis and clinical signiﬁcance may be different from
early reactivation.335
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Background: Disseminated fungal infection is a major cause
of morbidity and mortality in children undergoing HCT.
Anti-fungal prophylaxis with intravenous micafungin has a
distinct advantage over amphotericin-B and oral triazoles
due to its better safety proﬁle, speciﬁcally in terms of hepatic
and renal toxicity, and lack of drug-drug interactions
